Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis

Renal impairment (RI) is common in patients with multiple myeloma (MM) and new therapies that can improve renal function are needed. The phase III IKEMA study (clinicaltrials gov. Identifier: NCT03275285) investigated isatuximab (Isa) with carfilzomib and dexamethasone (Kd) versus Kd in relapsed MM...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Marcelo Capra, Thomas Martin, Philippe Moreau, Ross Baker, Ludek Pour, Chang-Ki Min, Xavier Leleu, Mohamad Mohty, Marta Reinoso Segura, Mehmet Turgut, Richard LeBlanc, Marie-Laure Risse, Laure Malinge, Sandrine Schwab, Meletios Dimopoulos
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Ferrata Storti Foundation 2021-10-01
Schriftenreihe:	Haematologica
Online-Zugang:	https://haematologica.org/article/view/10427
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!